{"id":982931,"date":"2026-07-20T16:18:42","date_gmt":"2026-07-20T20:18:42","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-present-at-the-canaccord-genuity-46th-annual-growth-conference\/"},"modified":"2026-07-20T16:18:42","modified_gmt":"2026-07-20T20:18:42","slug":"arcturus-therapeutics-to-present-at-the-canaccord-genuity-46th-annual-growth-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-present-at-the-canaccord-genuity-46th-annual-growth-conference\/","title":{"rendered":"Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Arcturus Therapeutics to Present at the Canaccord Genuity 46<sup>th<\/sup> Annual Growth Conference<\/b><\/p>\n<p>SAN DIEGO&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nArcturus Therapeutics Holdings Inc. (the \u201cCompany\u201d, \u201cArcturus\u201d, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will present at the following investor conference in Boston, Massachusetts:<\/p>\n<p><b>Canaccord Genuity 46<sup>th<\/sup> Annual Growth Conference (Fireside Chat)<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nTuesday, August 11, 2026 (12:00 p.m. ET)<\/p>\n<\/li>\n<\/ul>\n<p>\nWebcast link can be found under Investor Relations\/Events section of Arcturus\u2019 <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fir.arcturusrx.com%2Finvestor-calendar&amp;esheet=54573687&amp;newsitemid=20260720082379&amp;lan=en-US&amp;anchor=website&amp;index=1&amp;md5=3716ea82b5e0b0c54bfd2021e78b3c67\">website<\/a>.<\/p>\n<p><b>About Arcturus<\/b><\/p>\n<p>\nFounded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics with enabling technologies: (i) LUNAR\u00ae lipid-mediated delivery, (ii) STARR\u00ae mRNA technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed KOSTAIVE\u00ae, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration with CSL Seqirus, U.S. BARDA for pandemic flu and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Arcturus\u2019 pipeline includes RNA therapeutic candidates to potentially treat cystic fibrosis (CF) and ornithine transcarbamylase (OTC) deficiency along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus\u2019 versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA (siRNA), circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus&#8217; technologies are covered by its extensive patent portfolio (over 500 patents and patent applications in the U.S., Europe, Japan, China, and other countries). For more information, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.ArcturusRx.com&amp;esheet=54573687&amp;newsitemid=20260720082379&amp;lan=en-US&amp;anchor=www.ArcturusRx.com&amp;index=2&amp;md5=70e110792c8ac75180d8441b35270d8e\">www.ArcturusRx.com<\/a>. Please connect with us on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Farcturusrx&amp;esheet=54573687&amp;newsitemid=20260720082379&amp;lan=en-US&amp;anchor=X&amp;index=3&amp;md5=2f73d39d2cc42bac0b964818dc69743e\">X<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Farcturus-therapeutics&amp;esheet=54573687&amp;newsitemid=20260720082379&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=4&amp;md5=84fdb92b1192b73788b35dacef3bcf97\">LinkedIn<\/a>.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260720082379r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260720082379\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260720082379\/en\/<\/a><\/span><\/p>\n<p><b>Arcturus Therapeutics<br \/>\n<br \/><\/b>Public Relations &amp; Investor Relations<br \/>\n<br \/>Neda Safarzadeh<br \/>\n<br \/>VP, Head of IR\/PR\/Marketing<br \/>\n<br \/>(858) 900-2682<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:IR@ArcturusRx.com\">IR@ArcturusRx.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Massachusetts California New York United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Infectious Diseases Health Genetics Pharmaceutical<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260720082379\/en\/2855483\/3\/arcturus-logo-blueback_%282%29.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference SAN DIEGO&#8211;(BUSINESS WIRE)&#8211; Arcturus Therapeutics Holdings Inc. (the \u201cCompany\u201d, \u201cArcturus\u201d, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will present at the following investor conference in Boston, Massachusetts: Canaccord Genuity 46th Annual Growth Conference (Fireside Chat) Tuesday, August 11, 2026 (12:00 p.m. ET) Webcast link can be found under Investor Relations\/Events section of Arcturus\u2019 website. About Arcturus Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics with enabling technologies: (i) &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-present-at-the-canaccord-genuity-46th-annual-growth-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-982931","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-present-at-the-canaccord-genuity-46th-annual-growth-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference SAN DIEGO&#8211;(BUSINESS WIRE)&#8211; Arcturus Therapeutics Holdings Inc. (the \u201cCompany\u201d, \u201cArcturus\u201d, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will present at the following investor conference in Boston, Massachusetts: Canaccord Genuity 46th Annual Growth Conference (Fireside Chat) Tuesday, August 11, 2026 (12:00 p.m. ET) Webcast link can be found under Investor Relations\/Events section of Arcturus\u2019 website. About Arcturus Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics with enabling technologies: (i) &hellip; Continue reading &quot;Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-present-at-the-canaccord-genuity-46th-annual-growth-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-20T20:18:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260720082379r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcturus-therapeutics-to-present-at-the-canaccord-genuity-46th-annual-growth-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcturus-therapeutics-to-present-at-the-canaccord-genuity-46th-annual-growth-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference\",\"datePublished\":\"2026-07-20T20:18:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcturus-therapeutics-to-present-at-the-canaccord-genuity-46th-annual-growth-conference\\\/\"},\"wordCount\":351,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcturus-therapeutics-to-present-at-the-canaccord-genuity-46th-annual-growth-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260720082379r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcturus-therapeutics-to-present-at-the-canaccord-genuity-46th-annual-growth-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcturus-therapeutics-to-present-at-the-canaccord-genuity-46th-annual-growth-conference\\\/\",\"name\":\"Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcturus-therapeutics-to-present-at-the-canaccord-genuity-46th-annual-growth-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcturus-therapeutics-to-present-at-the-canaccord-genuity-46th-annual-growth-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260720082379r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-07-20T20:18:42+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcturus-therapeutics-to-present-at-the-canaccord-genuity-46th-annual-growth-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcturus-therapeutics-to-present-at-the-canaccord-genuity-46th-annual-growth-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcturus-therapeutics-to-present-at-the-canaccord-genuity-46th-annual-growth-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260720082379r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260720082379r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arcturus-therapeutics-to-present-at-the-canaccord-genuity-46th-annual-growth-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-present-at-the-canaccord-genuity-46th-annual-growth-conference\/","og_locale":"en_US","og_type":"article","og_title":"Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference - Market Newsdesk","og_description":"Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference SAN DIEGO&#8211;(BUSINESS WIRE)&#8211; Arcturus Therapeutics Holdings Inc. (the \u201cCompany\u201d, \u201cArcturus\u201d, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will present at the following investor conference in Boston, Massachusetts: Canaccord Genuity 46th Annual Growth Conference (Fireside Chat) Tuesday, August 11, 2026 (12:00 p.m. ET) Webcast link can be found under Investor Relations\/Events section of Arcturus\u2019 website. About Arcturus Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics with enabling technologies: (i) &hellip; Continue reading \"Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-present-at-the-canaccord-genuity-46th-annual-growth-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2026-07-20T20:18:42+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260720082379r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-present-at-the-canaccord-genuity-46th-annual-growth-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-present-at-the-canaccord-genuity-46th-annual-growth-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference","datePublished":"2026-07-20T20:18:42+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-present-at-the-canaccord-genuity-46th-annual-growth-conference\/"},"wordCount":351,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-present-at-the-canaccord-genuity-46th-annual-growth-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260720082379r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-present-at-the-canaccord-genuity-46th-annual-growth-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-present-at-the-canaccord-genuity-46th-annual-growth-conference\/","name":"Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-present-at-the-canaccord-genuity-46th-annual-growth-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-present-at-the-canaccord-genuity-46th-annual-growth-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260720082379r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-07-20T20:18:42+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-present-at-the-canaccord-genuity-46th-annual-growth-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-present-at-the-canaccord-genuity-46th-annual-growth-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-present-at-the-canaccord-genuity-46th-annual-growth-conference\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260720082379r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260720082379r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arcturus-therapeutics-to-present-at-the-canaccord-genuity-46th-annual-growth-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/982931","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=982931"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/982931\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=982931"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=982931"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=982931"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}